Evidence map›Paper›PMID 38497775›Full record

ArticleBioanalysis2024

Novel assay format for total anti-adeno-associated virus antibody detection with low capsid consumption and built-in specificity control.

Uwe Wessels, Florian Neff, Julia Fakhiri, Klaus Mayer, Ulrich Brinkmann, Kay Stubenrauch

Open access · hybridAbstract read
In one paragraph

Article in Bioanalysis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Uwe WesselsRoche Pharma Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center, Munich, Germany.ORCID 0009-0001-5186-8657
Florian NeffRoche Pharma Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center, Munich, Germany.ORCID 0009-0005-2073-0208
Julia FakhiriRoche Pharma Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center, Munich, Germany.ORCID 0000-0002-2517-9348
Klaus MayerRoche Pharma Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center, Munich, Germany.ORCID 0000-0001-9853-2299
Ulrich BrinkmannRoche Pharma Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center, Munich, Germany.ORCID 0000-0002-5558-0212
Kay StubenrauchRoche Pharma Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center, Munich, Germany.ORCID 0000-0003-3371-183X
Roche Pharma AG (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, ViralDependovirusMacaca fascicularisAnimalsAntigen-Antibody ComplexCapsidHumansAntibodies, ViralAntigen-Antibody Complexgene therapyimmune complex assayimmunogenicitytotal anti-AAV antibody assay

Identifiers

PMID38497775
PMCPMC11216498
OpenAlexW4392915899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.